Abstract presented at the American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2013; Chicago, IL.
Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer
Version of Record online: 6 AUG 2013
© 2013 American Cancer Society
Volume 119, Issue 21, pages 3753–3760, 1 November 2013
How to Cite
Eaton, B. R., Kim, S., Marcus, D. M., Prabhu, R., Chen, Z., Ramalingam, S. S., Curran, W. J. and Higgins, K. A. (2013), Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer. Cancer, 119: 3753–3760. doi: 10.1002/cncr.28267
- Issue online: 18 OCT 2013
- Version of Record online: 6 AUG 2013
- Manuscript Accepted: 6 JUN 2013
- Manuscript Revised: 5 JUN 2013
- Manuscript Received: 13 MAY 2013
- prophylactic cranial irradiation;
- small cell;
- lung cancer;
Prophylactic cranial irradiation (PCI) improves survival in patients with limited-stage small cell lung cancer (SCLC) who have a complete response to chemotherapy and radiotherapy, yet to the best of the authors' knowledge, data specific to the elderly population are lacking.
Using the Surveillance, Epidemiology, and End Results (SEER) database, the authors identified 1926 patients aged ≥ 70 years who were diagnosed with limited-stage SCLC between 1988 and 1997. Overall survival (OS) for patients who received PCI versus those who did not were estimated using the Kaplan-Meier method and compared with the log-rank test. A Cox proportional hazards model was further fitted to estimate the effect of PCI on OS after adjusting for age, race, sex, tumor size, lymph node status, stage of disease, and receipt of thoracic radiotherapy and surgery.
The median age of the patients was 75 years (range, 70 years-94 years) and 138 patients (7.2 %) received PCI. The 2-year and 5-year OS rates were 33.3% (95% confidence interval [95% CI], 25.6%-41.2%) and 11.6% (95% CI, 6.9%-17.6%), respectively, among patients who received PCI versus 23.1% (95% CI, 21.2%-25.1%) and 8.6% (95% CI, 7.3%-9.9%), respectively, among patients who did not receive PCI (P = .028). On multivariable analysis, PCI was found to be an independent predictor of OS (hazards ratio, 0.72; 95% CI, 0.54-0.97 [P = .032]). On subgroup analysis, PCI remained an independent predictor of OS among patients aged ≥ 75 years, but not among patients aged ≥ 80 years.
The receipt of PCI is associated with improved OS in patients aged ≥ 70 years with SCLC, suggesting that the benefit of PCI is maintained in the elderly population. Cancer 2013;119:3753–3760. © 2013 American Cancer Society.